Trial reportLeukemia2016
Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment.
Trial report in Leukemia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 55 citations in OpenAlex.
- Allogeneic stem cell transplantation for chronic myeloid leukemia in the TKI era: population-based data from the Swedish CML registry.Bone marrow transplantation · 2019Trial
- Trial
- Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.The New England journal of medicine · 2017Trial
- Allogeneic transplantation for CML blast phase: Learnings over last decade from a single centre in North India.Annals of hematology · 2025Article
- Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy.Frontiers in oncology · 2024Review
- Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review.Journal of blood medicine · 2023Review
- Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.Leukemia · 2022Review
- Treatment-Free Remission-A New Aim in the Treatment of Chronic Myeloid Leukemia.Journal of personalized medicine · 2021Review
- The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.Bone marrow transplantation · 2021Article
- The New ELN Recommendations for Treating CML.Journal of clinical medicine · 2020Review
- Chronic Myeloid Leukemia in 2020.HemaSphere · 2020Review
- High-risk additional chromosomal abnormalities at low blast counts herald death by CML.Leukemia · 2020Article
- Review
- The Connection Between Minor H Antigens and Neoantigens and the Missing Link in Their Prediction.Frontiers in immunology · 2020Review
- Molecular mechanisms for stemness maintenance of acute myeloid leukemia stem cells.Blood science (Baltimore, Md.) · 2019Article
- Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia.PloS one · 2019Article
- Article
- Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy.Blood advances · 2017Article
- Article
- Innovation in hematology. Perspectives: CML 2016.Haematologica · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
60 authors at 20 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). Allogeneic hematopoietic stem cell transplantation (HSCT) is regarded as salvage therapy. This prospective randomized CML-study IIIA recruited 669 patients with newly diagnosed CML between July 1997 and January 2004 from 143 centers. Of these, 427 patients were considered eligible for HSCT and were randomized by availability of a matched family donor between primary HSCT (group A; N=166 patients) and best available drug treatment (group B; N=261). Primary end point was long-term survival. Survival probabilities were not different between groups A and B (10-year survival: 0.76 (95% confidence interval (CI): 0.69-0.82) vs 0.69 (95% CI: 0.61-0.76)), but influenced by disease and transplant risk. Patients with a low transplant risk showed superior survival compared with patients with high- (P<0.001) and non-high-risk disease (P=0.047) in group B; after entering blast crisis, survival was not different with or without HSCT. Significantly more patients in group A were in molecular remission (56% vs 39%; P=0.005) and free of drug treatment (56% vs 6%; P<0.001). Differences in symptoms and Karnofsky score were not significant. In the era of tyrosine kinase inhibitors, HSCT remains a valid option when both disease and transplant risk are considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.